Analysis of Urinary Thromboxane B2, 8-iso-prostane, PGD2 and PGE2 in Mast Cell Disease

Overview

About this study

Specific aims:

Measurement of urinary arachidonic acid metabolites such as prostaglandins PGD2, PGE2, 8-isoprostane and TBXB2 in mastocytosis.
Comparison of these novel markers to conventional markers of tryptase and the well characterized n-methyl histamine and 11β-prostaglandinF2α

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients with a diagnosis of systemic mastocytosis. Only systemic mastocytosis patients who are not taking cyclooxygenase or 5-lipoxygenase inhibitors will be included in this pilot study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Rohit Divekar, M.B.B.S., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Rohit Divekar, M.B.B.S., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials